NASDAQ: TECH. Your partner of choice in protein science

Transcription

1 NASDAQ: TECH Your partner of choice in protein science August 2015

2 Disclaimer Cautionary Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, benefits of investments and partnerships, business strategies and other matters. Such statements can be identified by words such as: expected, expects, expect, forecast, would, estimate, will, or similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see our latest Annual Report on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise. This presentation also contains non-gaap financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For definitions of applicable non-gaap financial measures and reconciliations of non-gaap financial information to GAAP financial information, see the Reconciliations of GAAP to Non-GAAP Financial Measures included in the Company s financial reports on Forms 10-Q and 10-K and related press releases. 2

3 Current Business Overview Global footprint Minneapolis, Minnesota, headquarters employees globally Offices in North America, Europe and Asia Fiscal Year Ends: June 30 FY 2014 Revenues: $358 MM FY 2014 Gross Margin: 70.3% FY 2014 Adj. Earnings: $125 MM FY 2014 Adjusted EPS: $3.39 Current Market Cap: $4.1 B Deep product portfolio and applications expertise Leadership position in cytokines/growth factors, immunoassays and small molecules Provider of biological reagents for most biomedical research instruments One of three primary manufacturers of clinical blood controls Key recent acquisitions: Bionostics, PrimeGene, Novus, ProteinSimple, CyVek and Cliniqa 3

4 Geographic Sites

5 Bio-Techne Organization Total Employees: 1,418 Bio-Techne Corporation (TECH) Minneapolis, MN No Employees Cliniqa San Marcos, CA 75 Employees R&D Systems, Inc. Minneapolis, MN 680 Employees Novus Biologicals Littleton, CO 75 Employees ProteinSimple Santa Clara, CA 228 Employees R&D Systems Europe Abingdon, UK 67 Employees Tocris Bioscience Bristol, UK 55 Employees R&D Systems Asia Shanghai, CN 31 Employees Bionostics, Inc. Devens, MA 102 Employees Boston Biochem Cambridge, MA 8 Employees BiosPacific Emeryville, CA 7 Employees R&D Systems GmbH Wiesbaden, DE 10 Employees R&D Systems France Lille, FR 2 Employees PrimeGene Shanghai, CN 45 Employees CyVek Wallingford, CT 33 Employees 5

6 FY15 Reportable Segments Biotechnology R&D Systems Tocris Boston Biochem BiosPacific PrimeGene Novus Clinical Controls CCD Minneapolis CCD Devens Cliniqa ~ 14% of Sales High 60s Gross Margin% Low-teens Op. Margin% ~ 18% of Sales Mid 40s Gross Margin% High 20s Op. Margin% ~ 68% of Sales High 70s Gross Margin% Low 50s Op. Margin% Protein Platforms ProteinSimple CyVek 6

7 Biotechnology Customer Segmentation North America Europe 55% of Biotech Sales 28% of Biotech Sales 17% 13% 38% Pharma/Biotech Academia 26% 57% Other 49% Diverse customer base with no customer representing >1.5% of sales 7

8 Core Products Life Cycle Revenue Years Since Product Launch 8

9 What Do Proteins Do? Act as energy and structural elements of cells Act as messengers between cells and organs Regulate the immune system Induce cellular differentiation and specialization Transport key cellular metabolites 9

10 Cytokines Soluble, regulatory proteins produced and secreted by cells, which act as chemical messengers and bind to specific cellular receptors 10

11 Business Transformation Infrastructure improvements Management team empowerment Operational efficiencies Deployment of capital Commercial execution VoC and KOL network HR process New products prioritization process 11

12 Five Pillars Strategy Core Products and Innovation Geographic Expansion Commercial Execution Operational Excellence Talent Retention and Recruitment 12 12

13 Increasing Value Through Innovation More complete and automated lab solutions (Next-gen instruments and adjacent markets) Business Value Media supplements, high-content screens, biochips, small molecules (Biopharma large-scale production and targeted screens) Recombinant Ab technology and epitope-targeted Abs (Companion Diagnostics) GMP and designer proteins (Biotherapeutics) Core Reagent Products Time 13

14 China Strategy Commercial Expansion of sales force Expansion of sales offices China for China Locally make products Local pricing policies Relationships Strong local KOL network Benefit from government programs 14

15 M&A Strategy Targets with ROIC > WACC Targets that fill perceived gaps Sound prioritization strategy Healthy hopper of targets 15

16 Bio-Techne Companies 16

17 Products and Technology Expansion Core Reagents Clinical Controls and IVD Protein Platforms Proteins Antibodies Assays Small Molecules Cell-Based Controls Low-cost protein manufacturing in China ~250,000 additional Abs and digital platform Immunoassay automation and multiplexing Blood chemistry controls 17

18 Conclusion Our business has strong, global brand recognition built on the solid reputation of being a quality reagents developer and supplier for the research and diagnostic markets We are positioning ourselves as a more complete solution provider to our research and clinical customers through the acquisition of strong brands and businesses that complement and leverage our core reagent business We believe this combination will create greater economic value to all of our stakeholders and drive new growth for Bio-Techne 18 18